Clinical Trials

446 enrolled 49 charts

Phase 1 Active not recruiting

Locally Advanced and Metastatic Solid Tumors

NCT03537690 2025-08-12

FID-007 in Treating Participants With Advanced Solid Tumors

50 enrolled

Phase 1/2 Active not recruiting

Advanced Malignant Solid Neoplasm

NCT05275777 2025-07-25

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

66 enrolled

BreastOther solid neoplasm

HER2-negative Breast Cancer

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Phase 1/2 Recruiting

306 enrolled

Advanced Solid Tumors

NCT05978492 2025-04-24

A Study of TXN10128 in Subjects With Solid Tumors

Phase 1 Recruiting

96 enrolled

GastrointestinalOther solid neoplasm

Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT04492033 2025-01-27

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Phase 1/2 Terminated

41 enrolled

P1b: Advanced Solid Tumors

NCT06139211 2024-12-20

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Recruiting

186 enrolled

Advanced Solid Tumor

NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Phase 2 Completed

13 enrolled

Phase 1/2 Not yet recruiting

Advanced Solid Tumors

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

380 enrolled

Phase NA Not yet recruiting

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06649448 2024-10-18

EF-001

200 enrolled

Solid Tumor Cancer

NCT03154294 2024-07-26

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

19 enrolled 16 charts

Advanced Solid Tumor

NCT04761601 2024-03-13

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

32 enrolled

CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Advanced Solid Tumor

NCT01505569 2024-02-26

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Phase NA Completed

44 enrolled

Brain Neoplasms, Carcinoma, Renal Cell, Medulloblastoma, Neoplasms, Germ Cell and Embryonal, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Rhabdoid Tumor

NCT03834948 2023-08-22

AO-176 in Multiple Solid Tumor Malignancies

Phase 1/2 Completed

57 enrolled

Solid Tumor

NCT03892018 2023-05-22

The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

29 enrolled

Solid Tumor, Adult

NCT03588039 2023-05-19

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

34 enrolled

Solid Tumor

NCT03577704 2023-04-12

HLX07Ib/II

Phase 1/2 Completed

56 enrolled

Advanced Solid Tumors

NCT05214976 2022-12-22

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Phase 2 Unknown

64 enrolled

Advanced Solid Tumors

NCT01407562 2022-09-28

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

BreastOther solid neoplasm

34 enrolled

Unspecified Adult Solid Tumor - Protocol Specific

NCT03894540 2022-09-13

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

22 enrolled 27 charts

Solid Tumor

NCT04742036 2022-08-19

Capivasertib China PK Study

16 enrolled

Advanced Solid Tumours

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

BreastGenitourinaryOther solid neoplasmThoracic

210 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

35 enrolled

Recurrent Malignant Solid Neoplasm

NCT04035473 2022-04-13

A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

42 enrolled 21 charts

Solid Tumor

NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Phase 2 Completed

48 enrolled 17 charts

Malignant Solid Tumor

NCT02730481 2021-09-13

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

38 enrolled

Solid Tumor

NCT04180384 2021-07-29

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Phase 2 Completed

44 enrolled

Solid Tumor

NCT04802980 2021-07-28

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

Phase 1 Unknown

72 enrolled

Solid Tumor

NCT01240655 2020-12-19

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

76 enrolled

Solid Tumors

NCT01369433 2020-09-01

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Phase NA Terminated

225 enrolled 7 charts

Solid Tumors

NCT01525602 2020-07-16

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

74 enrolled 22 charts

Solid Tumors

NCT01862328 2020-06-22

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

64 enrolled 21 charts

Other solid neoplasmThoracic

Solid Tumors

NCT03920839 2020-04-24

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1 Withdrawn

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT01548924 2020-04-17

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

13 enrolled

Solid Tumors

NCT02358200 2020-01-10

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer